3,094
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Incidence, Prognostic Factors, and Survival of Patients with Renal Cancer: A Population-Based Study

, , &
Article: 2197506 | Received 23 Sep 2022, Accepted 19 Mar 2023, Published online: 09 Apr 2023

References

  • Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):1–9. doi:10.3322/caac.21654.
  • Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
  • Haifler M, Neheman A, Zisman A. Has stage migration in renal cancer run its course? A SEER database analysis. Clin Genitourin Cancer. 2020;18(4):e368–e373. doi:10.1016/j.clgc.2020.01.005.
  • Gandaglia G, Ravi P, Abdollah F, et al. Contemporary incidence and mortality rates of kidney cancer in the United States. Can Urol Assoc J. 2014;8(7–8):247–252. doi:10.5489/cuaj.1760.
  • Patel AR, Prasad SM, Shih YC, Eggener SE. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012;187(6):1978–1983. doi:10.1016/j.juro.2012.01.121.
  • Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539(7627):112–117. doi:10.1038/nature19796.
  • Burke HB. Outcome prediction and the future of the TNM staging system. J Natl Cancer Inst. 2004;96(19):1408–1409. doi:10.1093/jnci/djh293.
  • Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi:10.1245/s10434-010-0985-4.
  • Park YH, Lee SJ, Cho EY, et al. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol. 2019;30(12):2011. doi:10.1093/annonc/mdz223.
  • Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/jco.2007.12.9791.
  • Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589. doi:10.1001/jamasurg.2018.0501.
  • Turajlic S, Swanton C, Boshoff C. Kidney cancer: the next decade. J Exp Med. 2018;215(10):2477–2479. doi:10.1084/jem.20181617.
  • Bradley AJ, Maskell GF, Mannava A, Pollard A, Welsh T. Routes to diagnosis and missed opportunities in the detection of renal cancer. Clin Radiol. 2021;76(2):129–134. doi:10.1016/j.crad.2020.11.005.
  • Zhou Y, Abel GA, Hamilton W, Singh H, Walter FM, Lyratzopoulos G. Imaging activity possibly signalling missed diagnostic opportunities in bladder and kidney cancer: a longitudinal data-linkage study using primary care electronic health records. Cancer Epidemiol. 2020;66:101703. doi:10.1016/j.canep.2020.101703.
  • Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. doi:10.1016/j.eururo.2018.08.036.
  • Al-Bayati O, Hasan A, Pruthi D, Kaushik D, Liss MA. Systematic review of modifiable risk factors for kidney cancer. Urol Oncol. 2019;37(6):359–371. doi:10.1016/j.urolonc.2018.12.008.
  • Abou Elkassem AM, Lo SS, Gunn AJ, et al. Role of imaging in renal cell carcinoma: a multidisciplinary perspective. Radiographics. 2021;41(5):1387–1407. doi:10.1148/rg.2021200202.
  • Patel HD, Gupta M, Joice GA, et al. Clinical stage migration and survival for renal cell carcinoma in the United States. Eur Urol Oncol. 2019;2(4):343–348. doi:10.1016/j.euo.2018.08.023.
  • Takagi T, Kondo T, Tanabe K. Stage migration of renal cell carcinoma at a single Japanese university hospital: 24-year study. Int J Urol. 2014;21(4):429–430. doi:10.1111/iju.12300.
  • Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257. doi:10.1038/nrurol.2010.46.
  • Lughezzani G, Paciotti M, Fasulo V, Casale P, Saita A. Gender-specific risk factors for renal cell carcinoma: a systematic review. Curr Opin Urol. 2019;29(3):272–278. doi:10.1097/mou.0000000000000603.
  • Mancini M, Righetto M, Baggio G. Gender-related approach to kidney cancer management: moving forward. IJMS. 2020;21(9):3378. doi:10.3390/ijms21093378.
  • Peired AJ, Campi R, Angelotti ML, et al. Sex and gender differences in kidney cancer. Clin Exp Evid Cancers (Basel). 2021;13(18):4588. doi:10.3390/cancers13184588.
  • Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol. 2017;71(4):606–617. doi:10.1016/j.eururo.2016.08.060.
  • Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011;59(4):543–552. doi:10.1016/j.eururo.2010.12.013.
  • Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524. doi:10.3322/caac.21411.
  • Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337. doi:10.1172/jci83871.